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Subcutaneous liver tissue engineering is an attractive and minimally invasive approach used 2 
for curative treat hepatic failure and inherited liver diseases. However, graft failure occurs 3 
frequently due to insufficient infiltration of blood vessels (neoangiogenesis), while the 4 
maintenance of hepatocyte phenotype and function requires in vivo development of the 5 
complex cellular organization of the hepatic lobule. Here we describe a subcutaneous human 6 
liver construction allowing for rapidly vascularized grafts by transplanting engineered cellular 7 
sheets consisting of human primary hepatocytes adhered onto a fibroblast layer. The 8 
engineered hepatocyte/fibroblast sheets (EHFSs) showed superior expression levels of 9 
vascularization-associated growth factors (vascular endothelial growth factor, transforming 10 
growth factor beta 1, and hepatocyte growth factor) in vitro. EHFSs developed into 11 
vascularized subcutaneous human liver tissues (VSLTs) contained glycogen stores, 12 
synthesized coagulation factor IX, and showed significantly higher synthesis rates of 13 
liver-specific proteins (albumin and alpha 1 anti-trypsin) in vivo than tissues from 14 
hepatocyte-only sheets. The present study describes a new approach for vascularized human 15 
liver organogenesis under mouse skin. This approach could prove valuable for establishing 16 





   Construction of functional organs with capillary networks in vitro and in vivo is an 2 
attractive for the ultimate goal of regenerative medicine [1–6]. Construction of the 3 
transplantable liver tissue is clearly essential to establish systems necessary to treat liver 4 
disease using regenerative medicine. However, the reconstruction of liver structures and 5 
maintenance of their functions in vitro and in vivo are extremely difficult because the liver 6 
tissue contains complex liver-specific structures and displays a wide variety of functions [7]. 7 
  To overcome the problem that liver-specific functions of cultured hepatocytes decrease 8 
quickly, many researchers have reported that long-term maintenance of liver-specific 9 
functions was achieved using co-culture and/or 3D culture [8–12]. In addition, the 10 
reconstruction of liver sinusoids in vitro has been achieved by tri-culture of hepatocytes, 11 
hepatic stellate cells, and endothelial cells (ECs) on a microporous polyethylene terephthalate 12 
membrane [13]. However, the size of the reconstructed liver tissue has usually been limited 13 
because hepatocytes consume oxygen at a particularly high rate [14,15]. Several researchers 14 
have demonstrated vascular fabrication in cultured tissue using co-culturing with ECs [3], 15 
printed rigid 3D filament networks of carbohydrate glass [4], and decellularized liver matrix 16 
[16]. However, it has been difficult to construct a functional vascularized liver tissue in vitro. 17 
   The construction of the liver tissue in vivo also presents the need for a vascular bed and 18 
neovascularization into the transplanted tissue to ensure efficient engraftment and 19 
maintenance of proper function. Toward this goal, three-dimensional cell aggregates are 20 
usually transplanted into the omental pouch or subrenal capsule, where local blood vessels 21 
with high angiogenic potential facilitate tissue survival [2,5,17–19]. In addition, recellularized 22 
liver graft using decellularized technology were transplantable organs [16]. However, there 23 
are several issues in these transplantation sites such as risks associated with the type of 24 
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surgery involved in blood vessels. 1 
   Vascularized tissue construction under the skin is widely regarded as potentially the safest, 2 
quickest, least invasive grafting strategy, retransplantation, and easy removal of transplanted 3 
tissues in case of graft failure or tumorigenic transformation [18,20–22], but it has yet to be 4 
achieved, because graft failure occurs frequently due to insufficient infiltration of blood 5 
vessels [2,5,17,23]. To overcome the issue, previous papers have showed remarkable 6 
approaches using cell sheet engineering and neovascularized method. Repeated 7 
transplantation of mouse primary hepatocyte sheets after per-transplant vascularization under 8 
skin by implanting a device for the continuous release of angiogenic growth factors [24]. 9 
Others showed reconstructed tissue with capillary networks in vitro connected with local 10 
blood vessels by surgical methods [3,16]. However, these methods have limitations of 11 
promptness of treatment such as acute liver disease because it takes at least several days to 12 
prepare transplantable tissue from hepatocytes and to prepare the vascular bed. 13 
   In this study, we demonstrate a simple and rapid method for producing vascularized 14 
subcutaneous human liver tissue (VSLT) in vivo by transplantation of engineered 15 
hepatocyte/fibroblast sheets (EHFSs) without addition of stem cells or ECs. We show the 16 
maintenance of liver-specific functions and reconstructed structures. 17 
 18 
 19 
2. Materials and methods 20 
2.1. Human primary hepatocyte isolation 21 
   Ethical approval was obtained from the Human Ethics Review Committee of Nagasaki 22 
University School of Medicine for human hepatocyte isolation, storage, culture, and 23 
transplantation into mice, and informed consent was obtained from all human hepatocyte 24 
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donors. Resected human liver tissues (approximately 30 g) were obtained during liver surgery 1 
(Table 1). Human primary hepatocytes were isolated from human liver tissues by perfusing 2 
collagenase (130 U/mL, Wako Pure Chemical, Osaka, Japan) [25,26]. The cell suspension in 3 
25% Percoll Plus solution (GE Healthcare, Tokyo) was centrifuged at 70 × g for 7 min at 4°C 4 
to further purify hepatocytes and enrich viable cells. Cell viability was determined by the 5 
trypan blue exclusion test, and suspensions with >80% viable cells were used for culture and 6 
construction of sheets. The medium for isolation was Dulbecco's modified Eagle's medium 7 
(Wako Pure Chemical) supplemented with 10% fetal bovine serum (FBS), 10 mM 8 
4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid, 2 mM L-glutamine, 100 U/mL penicillin, 9 
and 100 µg/mL streptomycin (all from Invitrogen, Carlsbad, CA). 10 
 11 
2.2. Human fibroblast culture 12 
   Normal human diploid fibroblast TIG-118 cells, which derived from human skin (female, 13 
12 years old), were purchased from Health Science Research Resources (JCRB0535; Osaka, 14 
Japan) and cultured as a continuous monolayer in 90-mm tissue culture dishes (Nalgene Nunc 15 
International, Rochester, NY, USA) containing 10 mL Minimum Essential Medium 16 
(Invitrogen) supplemented with 10% FBS, 2 mM L-glutamine, 100 U/mL penicillin, and 100 17 
µg/mL streptomycin. The TIG-118 cells at 90% confluence were treated with 0.25% 18 
trypsin-EDTA (Invitrogen), and the cell suspension was obtained. 19 
 20 
2.3. Human hepatocyte sheet construction 21 
   Two types of human primary hepatocyte sheets were constructed using 22 
temperature-responsive culture dishes (TRCDs) (UpCell; CellSeed, Tokyo) in accordance 23 
with our previous report [27]. To construct EHFSs, human primary hepatocytes obtained as 24 
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 (1.0 × 10
6
 cells/dish) onto a confluent layer of 1 




 (2.2 × 10
5
 cells/dish) onto 2 
non-coated TRCDs (Fig. 1A). To construct hepatocyte-only sheets (HSs), hepatocytes were 3 
inoculated onto TRCDs coated with FBS. All the human primary hepatocytes were cultured in 4 
Supplemented ISOM’s Media (BD Biosciences, San Jose, CA) supplemented with 10% FBS, 5 
100 U/mL penicillin, and 100 µg/mL streptomycin until 24 h after inoculation. The 6 
Supplemented ISOM’s Media was replaced with 2 mL of Hepato-STIM Culture Medium (BD 7 
Biosciences) supplemented with 10% FBS, 2 mM L-glutamine, 100 U/mL penicillin, and 100 8 
µg/mL streptomycin. This medium was changed 1 and 3 days after inoculation. All cells were 9 
cultured under a humidified atmosphere of 5% CO2 and 95% air at 37°C. After 4 days of 10 
hepatocyte culture or co-culture, plates were incubated at 20°C to induce the formation of 11 
detached cell sheets. Fibroblast-only sheets (FSs) were also constructed by following the 12 
same process. Samples of media were collected after 1 to 3 days of culture and stored at 13 
−20°C until assayed for human GFs involved in angiogenesis. 14 
 15 
2.4. Hepatocyte sheet transplantation under mouse skin 16 
   Ethical approval for hepatocyte sheet transplantation was obtained from the Animal Care 17 
and Use Committee and the Recombinant DNA Experiment Safety Committee of Nagasaki 18 
University and performed according to all protocols approved by the Regulations. The 19 
abdominal subcutaneous space for transplantation was created by a tear between the 20 
cutaneous and skeletal muscle layer in NOD SCID mice (NOD.CB17-Prkdc
scid
/J; Charles 21 





Central Institute for Experimental Animals, Kanagawa, Japan) (males, 6–17 weeks old, 23 
weighing 20–35 g) (Fig. 1B). The hepatocyte-containing sheets (EHFSs or HSs) after 4 days 24 
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of culture were subcutaneously-transplanted using a support membrane or a glass plate to 1 
facilitate handling, and the supporters were removed at several miniatures after contact of cell 2 
sheet into subcutaneous site. One cell sheet (1.0 × 10
6
 hepatocytes) was transplanted into each 3 
mouse. To demonstrate the advantages of EHFS, a suspension consisting of hepatocytes (1.0 4 
× 10
6
 cells) and fibroblasts (1.5 × 10
6
 cells) was injected under a mouse’s skin. At 1, 2, and 4 5 
weeks after transplantation, 100–200 µL of blood was collected from the tail of NOD SCID 6 
mice, and the serum samples were stored at −20°C until assayed for the concentration of 7 
liver-specific human proteins. 8 
 9 
2.5. Histology 10 
   Cell sheets and VSLTs in NOD SCID mice were fixed with 4% paraformaldehyde 11 
phosphate buffer solution (Wako Pure Chemical) for 24 h to 72 h. Fixed samples were 12 
embedded in paraffin, cut into 5-µm cross-sections, mounted on MAS-coated slides 13 
(Matsunami Glass, Osaka, Japan), and deparaffinized for standard histological staining with 14 
hematoxylin and eosin (HE), orange G, azocarmin G, and aniline blue (Azan), or periodic 15 
acid-Schiff (PAS) (all from Muto Pure Chemicals, Tokyo). For immunostaining, sections were 16 
heated in 10 mM Tris-HCl buffer (pH 9.0) containing 1 mM EDTA using a microwave or 17 
autoclave for antigen retrieval, incubated in 3% hydrogen peroxide solution for 10 min to 18 
quench endogenous peroxidase activity or Biotin-Blocking System (Dako Japan, Kyoto), and 19 
then blocked in Tris-buffered saline (TBS) containing 5% bovine serum albumin (BSA) and 20 
0.1% Tween 20 for 1 h at room temperature. Blocked sections were incubated overnight at 21 
4°C in TBS + 5% BSA, 0.1% Tween 20, and with the following antibodies: rabbit anti-human 22 
albumin (hALB) (ab2406; 1:3000), mouse anti-human alpha 1-antitrypsin (hA1AT) (ab9399; 23 
1:1500), sheep anti-human blood coagulation factor IX (hF9) (ab128048; 1:100), mouse 24 
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anti-cytokeratin 18 (CK18) (ab668; 1:500), mouse anti-human vimentin (hVim) (ab8069; 1 
1:500), rabbit anti-cluster of differentiation 31 (CD31) (ab28364; 1:50), rabbit anti-human 2 
CD31 (hCD31) (ab76533; 1:250), rabbit anti-Ki67 (ab16667; 1:100) (all from Abcam, 3 
Cambridge, MA), or rabbit anti-E-cadherin (E-cad) (sc-7870; 1:100) (Santa Cruz 4 
Biotechnology, Santa Cruz, CA). Sections were then incubated for 1 h at room temperature in 5 
an appropriate secondary antibody: horseradish peroxidase (HRP)-conjugated goat anti-rabbit 6 
IgG (A0545; 1:300), biotin-conjugated goat anti-rabbit IgG (B8895; 1:800), fluorescein 7 
isothiocyanate (FITC)-conjugated goat anti-rabbit IgG (F9887; 1:320), FITC-conjugated 8 
rabbit anti-mouse IgG (F9137; 1:200), tetramethylrhodamine isothiocyanate 9 
(TRITC)-conjugated rabbit anti-mouse IgG (T2402; 1:400), FITC-conjugated ExtrAvidin 10 
(E2761; 1:80), TRITC-conjugated ExtrAvidin (E3011; 1:150) (all from Sigma-Aldrich Japan, 11 
Tokyo), or biotin-conjugated donkey anti-sheep IgG (ab97123; 1:500) (Abcam). 12 
HRP-conjugated secondary binding was visualized using the Dako liquid DAB+ substrate 13 
chromogen system (Dako Japan). Nuclei stained with hematoxylin or 14 
4’,6-diamidiono-2-phenylindole (DAPI; DOJINDO, Kumamoto, Japan). Slides stained with 15 
HRP-conjugated secondary antibodies were mounted with Permount (Fisher Scientific, 16 
Atlanta, GA) and slides stated with fluorophore-conjugated secondary antibodies with 17 
ProLong gold antifade mounting medium (Invitrogen). Bright-field and fluorescence images 18 
were captured using an optical microscope (BX53; Olympus, Tokyo) and a confocal laser 19 
scanning microscope (FV10i; Olympus), respectively. 20 
 21 
2.6. Sheet size and thickness measurements 22 
   The exterior photographs of cell sheets were captured to evaluate the cell sheet sizes [27]. 23 
The sizes of cell sheets were calculated as the ratio of the cell sheet area to the original TRCD 24 
11 
 
culture surface area. To evaluate the thicknesses of the cell sheets, the HE stained 1 
cross-sectional images of the cell sheets were captured. These areas and thickness were 2 
measured using the NIS-Elements software program (Nikon, Tokyo). 3 
 4 
2.7. Ultrastructural analysis (TEM) 5 
   EHFSs and VSLTs in NOG mice at 2 weeks after transplantation were fixed with 2.5% 6 
glutaraldehyde in 0.1 M phosphate buffer (pH 7.4), post-fixed in phosphate-buffered 1% 7 
osmium tetroxide for 2 h at 4°C, and then dehydrated through a graded ethanol series. The 8 
dehydrated samples were embedded in Epon 812 (TAAB Laboratories Equipment Ltd., 9 
Berkshire, England). Ultrathin sections were cut with a diamond knife on an ultramicrotome 10 
(Ultracut S, Leica, Austria), double-stained with uranyl acetate and lead nitrate, then imaged 11 
under an electron microscope (JEM-1200EX, JEOL, Tokyo) at an accelerating voltage of 12 
60−80 kV. 13 
 14 
2.8. Human growth factors and liver-specific functions assay (ELISA) 15 
   Human platelet-derived growth factor BB (PDGF-BB), vascular endothelial growth factor 16 
(VEGF), transforming growth factor beta 1 (TGF-β1), basic fibroblast growth factor (bFGF), 17 
hepatocyte growth factor (HGF), and epidermal growth factor (EGF) in culture media 18 
samples were measured by using DuoSet ELISA Development Systems (R&D Systems, 19 
Minneapolis, MN) according to the manufacturer’s instructions. Human ALB and A1AT in 20 
serum samples of NOD SCID mice were measured using rabbit anti-human albumin (6 21 
μg/mL), HRP-conjugated goat anti-human albumin (10 μg/mL) (MP Biomedicals, 22 
LLC-Cappel products, Irvine, CA), goat anti-human A1AT (5 μg/mL; Bethyl Laboratories, 23 
Montgomery, TX), or HRP-conjugated goat anti-human A1AT (7 μg/mL; Fitzgerald Industries 24 
12 
 
International, Inc., Concord, MA). 1 
 2 
2.9. Statistical analysis 3 
   Data are presented as mean ± standard deviation (SD) from at least 6 time points. Means 4 
of continuous numerical variables were compared by Welch’s t-test, one-way analysis of 5 
variance (ANOVA) (Tukey's multiple comparison test), or two-way ANOVA (Sidak's multiple 6 
comparison test) (GraphPad Prism version 6.00 for Windows; GraphPad Software, San Diego, 7 
CA). Values of **P < 0.01 and *P < 0.05 were considered statistically significant. 8 
 9 
 10 
3. Results 11 
3.1. Characteristic morphologies of the EHFS 12 
   Human primary adult hepatocytes attached onto the TIG-118 cell layer within 1 h, and 13 
these adherent hepatocytes eventually assumed the typical cuboidal shape of mature 14 
hepatocytes (Fig. 2A). In contrast, primary hepatocytes cultured alone on a FBS-coated 15 
TRCD surface required approximately 4 h to adhere. It normally takes at least 4 days for 16 
cultured hepatocytes alone to become fully confluent. EHFSs and HSs were harvested by 17 
reducing the culture temperature from 37°C to 20°C for approximately 1 to 2 h (for EHFSs) 18 
or 4 to 12 h (for HSs) on day 4 (Fig. 2B). The reduced temperature initiated the natural 19 
detachment of the cells from the edge of the TRCD surface, resulting in floating cell sheets in 20 
the culture medium that shrank to approximately 20% of the original culture surface area (Fig. 21 
2B, C). The area of EHFSs were slightly-larger than those of HSs. 22 
   Histological cross-sections of both types of hepatocyte sheet showed ubiquitous 23 
hepatocyte survival as revealed by HE staining, as well as hepatocytic expression of both 24 
13 
 
hALB and the hepatocyte marker CK18 (Fig. 2D). In EHFSs, almost all hVim-positive 1 
fibroblasts (particularly those displaying mesenchymal cell cytoskeleton markers) had 2 
migrated from the bottom to the top of the sheet during the 4 days in co-culture with 3 
hepatocytes. The cells present in HSs were hVim-negative. The endothelial cell marker 4 
hCD31 was expressed only at very low levels in EHFSs and HSs. These EHFSs were 5 
approximately 1.6-times thicker than HSs (Fig. 2E). Hepatocytes in EHFSs reconstructed bile 6 
canals (BCs), tight junctions (TJs), desmosomes (Ds), and gap junctions (GJs), and adhered to 7 
fibroblasts as revealed by TEM (Fig. 2F). 8 
 9 
3.2. Angiogenic growth factor syntheses in vitro 10 
   To indicate the possibility of using a one-step subcutaneous hepatocyte transplantation 11 
procedure without a pre-transplant vascularization step, synthesis rates of 12 
vascularization-associated growth factors in vitro were assayed. EHFSs exhibited significantly 13 
higher synthesis rates of the angiogenic factors VEGF, TGF-β1, and HGF than the HSs from 1 14 
to 3 days in culture (Fig. 3B, C, E). The synthesis of TGF-β1 and HGF from fibroblasts were 15 
upregulated and down-regulated, respectively, by co-culture with hepatocytes. In contrast, 16 
PDGF-BB, bFGF, and EGF were not detected in either type of cell sheet (Fig. 3A, D, F). 17 
 18 
3.3. VSLT construction process from EHFS 19 
   Time-dependent VSLTs were investigated by staining with HE, two types of CD31 20 
(non-specific species and human origin), and cell proliferation marker Ki67. The transplanted 21 
EHFSs were initially laminated and necrosis occurred at a part of hepatocytes on 1 day after 22 
transplantation (Fig. 4A). Although hepatocytes at the outer end of VSLTs were hypertrophic 23 
at 7 days, cells were rarely observed at 14 days after transplantation. ECs (CD31-positive) 24 
14 
 
were observed 7 days after transplantation, and many neovascular vessels (Ki67-positive ECs) 1 
grew into the liver tissue until 14 days (Fig. 4A−C). In contrast, little expression of Ki67 in 2 
hepatocytes was revealed (Fig. 4A). The transplanted EHFSs formed grossly-visible VSLT, 3 
which had numerous blood vessels at the edge by day 7 after transplantation (Fig. 4D). The 4 
VSLTs indicated an increased red color by day 14 after transplantation (Fig. 4E). 5 
 6 
3.4. Liver-specific structures of the VSLT 7 
   Indeed, VSLT of 100–300 μm thickness at 2 weeks after transplantation contained 8 
hepatocytes surrounded by collagen fibers as confirmed by HE and Azan staining, 9 
respectively (Fig. 5A). Moreover, VSLT had liver-specific features such as glycogen stores 10 
and hALB, hA1AT, and hF9 syntheses as revealed by PAS staining and immunostaining, 11 
respectively (Fig. 5A, B). The aggregated hepatocytes formed several linear structures 12 
surrounded by human fibroblasts (hVim-positive) and abundant blood vessels 13 
(hCD31-positive) and adherens junctions (E-cad) between hepatocytes (CK18-positive). TEM 14 
images of VSLTs showed that hepatocytes are adjacent to microvessels supported by 15 
fibroblasts through the microvilli (MVs) (Fig. 5C). The VSLTs constructed the ultrastructural 16 
features of mature liver, such as BCs and several types of cell adhesions (TJs and Ds). In 17 
contrast, transplanted HSs formed simple hepatocyte monolayers that covered only a small 18 
area of the transplant site (Fig. 5A). 19 
 20 
3.5. Liver-specific functions of the VSLT in vivo 21 
   The in vivo liver-specific functionality of transplanted EHFSs is underscored by the 22 
concentrations of human proteins detected in the sera of recipient mice. The hALB synthesis 23 
rate was approximately 23-times higher than that in liver tissue from transplanted HSs one 24 
15 
 
week after transplantation (Fig. 6A). Although there was a minor decrease after 1 
transplantation, the VSLTs maintained higher hALB and hA1AT expression levels for 4 weeks 2 
(Fig. 6A, B). The transplantation of EHFS was more effective than the transplantation of 3 
co-suspension of hepatocytes and fibroblasts (Fig. 6C). 4 
 5 
 6 
4. Discussion 7 
   Both types of hepatocyte sheets could be harvested at 4 days after the seeding of 8 
hepatocytes (Fig. 2B). Interestingly, EHFSs were more easily detached due to the forceful 9 
contraction of fibroblasts and formed thicker morphology (Fig. 2D, E). In addition, EHFSs 10 
could be harvested from TRCDs only one day after the seeding of hepatocytes onto fibroblast 11 
confluent (Supplementary Fig. 1A). The most rapid construction of EHFSs was achieved 12 
about 4 h after the inoculation of TIG-118 cells (Supplementary Fig. 1B). The TIG-118 cell 13 





), and EHFSs could be harvested soon after the adhesion of hepatocytes. These 15 
advantages of EHFS could aide in easy manipulation during transplantation and could be used 16 
for emergency such as acute liver failure. Similar advantages for rapid construction and sheet 17 
characteristics were described for our previously engineered HepaRG cell/fibroblast sheets 18 
compared to HepaRG cell sheets from monoculture [27]. 19 
   Subcutaneous transplantation of the EHFSs would allow for minimally invasive 20 
hepatocyte-based therapy as well as possible retransplantation and removal of grafts if 21 
necessary [18,20–22]. However, graft failure occurs frequently [2,5,17,23]. The major reason 22 
for engraftment failure has been the insufficient number of blood vessels at the site of 23 
transplantation and the lack of vascular infiltration into the new tissue. To overcome this 24 
16 
 
limitation, previous studies have induced subcutaneous vascularization by implanting a device 1 
for controlled release of acidic fibroblast growth factor, bFGF, or VEGF, but it took at least 10 2 
days for vascular bed formation [24,28,29]. Quite amazingly, grossly-visible VSLT, which 3 
had numerous blood vessels, were observed by day 7 after transplantation (Fig. 4D) without 4 
pre-transplant vascularization. This result will be caused by the continuous releasing of the 5 
angiogenic factors from the EHFSs (Fig. 3B, C, E) instead of implanting a device for 6 
subcutaneous vascularization. Furthermore, the mRNA expressions (VEGF, TGF-β1, and 7 
HGF) of VSLTs from EHFSs maintained at least 2 weeks after transplantation, and the 8 
expression levels compared favorably with those of EHFSs (Supporting information and 9 
Supplementary Fig. 2). 10 
   We show the model of VSLT construction in Fig. 7. The VSLTs were thick tissue 11 
comprising hepatocytes despite the low expression of Ki67 (Fig. 4A), which means that VSLT 12 
thickness resulted from the survival and self-aggregation of transplanted hepatocytes, 13 
followed by neoangiogenesis (Fig. 4B, C). The regulation of hepatocyte growth can be 14 
blamed on high TGF-β1 synthesis from fibroblasts (Fig. 3C) [30]. To improve the effect of 15 
subcutaneously transplanted hepatocytes, we should try to modify our system to allow the 16 
regulation of TGF-β1 synthesis. The aggregated hepatocytes in the outer end of VSLTs were 17 
hypertrophy at 7 days after transplantation because a temporary increasing of blood pressure 18 
will occur in the areas due to the discontinuity of blood vessels (Fig. 4A, D). The 19 
phenomenon was usually observed under high portal blood pressure condition after the partial 20 
hepatectomy [31]. Vascular network could perfuse blood when these discontinuous blood 21 
vessels connected with themselves; thus, the VSLTs indicated an increased red color (Fig. 4E). 22 
Hypertrophied hepatocytes were rarely observed at 14 days after transplantation (Fig. 4A) 23 
because the local blood pressure had decreased from vascular network formation. To reveal 24 
17 
 
the origin of ECs, the immunochemical staining (non-specific species CD31 and human 1 
CD31) of VSLTs at 7 and 14 days after EHFS transplantation were performed. As a result, 2 
almost all ECs at 7 days were from the host mice (non-specific species CD31-positive, 3 
hCD31-negative) (Fig. 4A). The number of CD31-positive cells at 14 days was higher than 4 
that at 7 days; thus, these vascular vessels grew into VSLTs from mice. However, 5 
hCD31-positive ECs could also be detected at 14 days. Very few human ECs in the cell 6 
suspension may proliferate during later period. 7 
   VSLTs showed high synthesis of liver-specific functions and reconstruction of structures 8 
(Fig. 5). At 2 weeks after EHFS transplantation, VSLTs consisted of several linearly located 9 
hepatocytes and abundant blood vessels, which were similar to hepatic lobule structures (Fig. 10 
5A, B) [7]. In detail, hepatocytes are adjacent to microvessels through MVs, which is 11 
remarkably similar to the space of Disse (Fig. 5C). These structures permit VSLTs of 300-μm 12 
thickness to remain alive despite exceeding the limit of cell sheet thickness for effective 13 
oxygen diffusion/supply (approximately 40 μm) [32–34]. Liver-specific ultrastructures, such 14 
as BCs, between hepatocytes were also reconstructed in vivo. These human hepatocytes 15 
expressed liver-specific functions in vivo, including hALB, hA1AT, and hF9 (Fig, 5B). In the 16 
future, VSLT could also assist in the development of several useful assays, such as novel 17 
systems to assess drug transport, and the treatment of hemophilia. 18 
   The human ALB and A1AT synthesis activities of VSLTs were exceedingly higher than 19 
those in the liver tissue derived from transplanted HSs (Fig, 6A, B). Takebe et al [2] reported 20 
that the kidney subcapsule was a superior transplantation site compared with various ectopic 21 
sites, such as cranium and mesentery. However, they also showed that human adult 22 
hepatocytes (4.0 × 10
6
 cells) transplanted under the kidney subcapsule of mouse could not 23 
keep producing high levels of hALB and showed a peak at day 15 (approximately 1200 24 
18 
 
ng/mL). Chen et al [5] reported that their system for creating human ectopic artificial liver 1 
was ineffective for engraftment to the subcutaneous space. In contrast, VSLTs showed high 2 
levels of function despite the fact that VSLTs consisted of no more than 1.0 × 10
6
 3 
subcutaneously implanted hepatocytes. At 4 weeks after transplantation, VSLTs maintained 4 
these functions (hALB, 1132 ± 553 ng/mL; hA1AT, 193 ± 62 ng/mL), although there were no 5 
significant differences. HE stained images of VSLT showed hepatocyte survival and support 6 
the high liver-specific protein synthesizes (Supplementary Fig. 3A). On the other hand, the 7 
hepatocytes from HS were not readily apparent (Supplementary Fig. 3B). EHFS was more 8 
effective than co-suspension, as evidenced by results from well engraftment of the sheet 9 
format cell organoid (Fig, 6C). Almost all hepatocyte at 1 week after co-suspension 10 
transplantation were hypertrophic and formed thin tissue (Supplementary Fig. 3C). This fact 11 
highlighted the benefit of hepatocyte sheet such as enough extracellular matrix components 12 
and well-graft on site without wide spreading. However, we were concerned that 13 
exceedingly-high TGF-β1 synthesis of EHFS may trigger a part of hepatocytes to be apoptosis 14 
[31] and possibly-caused this minor decrease. Thus, this cell therapy has the possibility of 15 
improvement in additional cell sources and/or medications for long-term cell therapy of 16 
chronic liver failure. 17 
   One of the most important differences from previous techniques is the safety of the cell 18 
sources. The use of mature hepatocytes and fibroblasts eliminates the risks of unanticipated 19 
differentiation fate, tumorigenic transformation [35–37], and tumor growth by mesenchymal 20 
stem cell accumulation at the tumor site [38,39]. Next, the VSLTs were constructed from 21 
easily cultured cells using simple procedures. This system employed normal human dermal 22 
fibroblasts, which are easily cultured and proliferate rapidly, and requires no separate in vitro 23 
or in vivo vascularization methods before transplantation, such as mixing human umbilical 24 
19 
 
vein endothelial cells with the cultured tissue and/or pre-implanting a bFGF-releasing device 1 
at the transplantation site. In addition, this system could allow for rapid large-scale production 2 
of transplantable tissue because it takes as little as 4 h for construction of EHFSs after seeding 3 
of fibroblasts. Such a system could be used in emergent circumstances associated with liver 4 
surgery, such as autologous hepatocyte transplantation, because EHFSs can be produced 5 
during the operation. This simple and rapid procedure is a major advance toward clinical 6 
application of subcutaneous liver tissue transplantation. Finally, more improvement of 7 
transplantation efficiency could require optimization of other cell sources, sheet forming 8 
process, combination of growth factors, and/or pre-transplant vascularization; thus, we will 9 
investigate these subjects as the next step for treatment liver diseases. Moreover, identical 10 
expression patterns of angiogenic factor synthesize in vitro and liver-specific functions in vivo 11 
were observed when HepaRG cells were employed instead of human primary hepatocytes to 12 
create EHFSs (Supplementary Fig. 4, 5). Thus, this versatile fibroblast system could be used 13 
for the construction of subcutaneous organs by using several functional cells such as islet of 14 
the pancreas. 15 
 16 
 17 
5. Conclusion 18 
   We demonstrate viable VSLT derived from simple one-time subcutaneous transplantation 19 
of EHFSs. This system, which consists of cell sheet technology and co-culturing fibroblasts 20 
without pre-transplant procedures, was able to overcome the low transplantation efficiency of 21 
previous subcutaneous transplantation procedures. In addition, the transplant site and cell 22 
types employed could realize goals for the procedure to be minimally invasive and drastically 23 
safe. The resulting VSLTs could be used for the treatment of acute hepatic failure and 24 
20 
 
inherited liver diseases. Furthermore, this system can be applied not only to hepatocytes but 1 
also to other cell types. Thus, our novel fibroblast system could be used to rapidly construct 2 
subcutaneous vascularized organs. 3 
 4 
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Figure Legends 1 
Fig. 1. Construction and transplantation of EHFSs. (A) Schematic of EHFS construction. (B) 2 
The processes of hepatocyte sheet transplantation under mouse skin. 3 
 4 
Fig. 2. Characterization of EHFSs. (A) Phase-contrast micrographs of hepatocytes cultured on 5 
TRCDs. Above, human primary hepatocytes and fibroblasts; below, hepatocytes alone. Scale 6 
bar, 100 μm. (B) Macroscopic and phase-contrast images of EHFSs and HSs. Scale bar, 100 7 
μm. (C) Areas (n ≥ 11 from 2 independent preparations) of EHFSs (open columns) and HSs 8 
(closed columns). Mean ± SD. (D) HE and immunofluorescence staining of sheet 9 
cross-sections. Scale bar, 50 μm. (E) Thicknesses (n ≥ 9 from 4 independent preparations) of 10 
EHFSs (open columns) and HSs (closed columns). Mean ± SD, **P < 0.01 (Welch’s t-test). 11 
(F) TEM images of EHFS cross-sections. Scale bar, 1 μm. Hep, hepatocyte; Fib, fibroblast; N, 12 
nucleus; MV, microvillus; BC, bile canal; TJ, tight junction; D, desmosome; GJ, gap junction; 13 
N.S., not significant. 14 
 15 
Fig. 3. In vitro synthesis rates of growth factors involved in angiogenesis. (A) Human 16 
PDGF-BB, (B) VEGF, (C) TGF-β1, (D) bFGF, (E) HGF, and (F) EGF (n ≥ 17 from 2 17 
independent cell preparations). Open, closed, and shaded columns represent EHFSs, HSs, and 18 
FSs, respectively. Mean ± SD, **P < 0.01 and *P < 0.05 (one-way ANOVA). N.D., not 19 
detected. 20 
 21 
Fig. 4. Development of VSLTs in vivo. (A) Temporal HE and immunohistochemical staining 22 
of VSLT cross-sections at 1, 7, and 14 days after EHFS transplantation. Scale bar, 100 μm. 23 
(B) Vessel area and (C) number of Ki67-positive ECs in VSLTs at 7 and 14 days after EHFS 24 
27 
transplantation (n = 6 from more than 4 independent cell preparations). Mean ± SD, *P < 0.05 1 
(Welch’s t-test). (D) Macroscopic image and phase-contrast micrograph of blood vessels in 2 
the VSLTs at 7 days after EHFS transplantation. Scale bar, 1 mm. (E) Macroscopic images of 3 
skin at 7 and 14 days after EHFS transplantation. Scale bar, 5 mm. The dashed lines indicate 4 
the VSLTs. 5 
6 
Fig. 5. Functional VSLTs under mouse skin at 2 weeks after transplantation. (A) HE, Azan, 7 
and PAS staining of VSLT cross-sections. Scale bar, 100 μm. (B) Immunofluorescence 8 
staining of VSLT cross-sections. Scale bar, 50 μm. (C) TEM images of VSLT cross-sections. 9 
Scale bar, 2 μm. Hep, hepatocyte; Fib, fibroblast; EC, endothelial cell; RBC, red blood cell, 10 
MV, microvillus; BC, bile canal; TJ, tight junction; D, desmosome. 11 
12 
Fig. 6. In vivo liver-specific functions in mice. (A) hALB and (B) hA1AT concentrations in 13 
NOD SCID mouse serum (n ≥ 10 from 2 independent cell preparations). (C) hALB 14 
concentrations in NOD SCID mouse serum at 1 week after transplantation (n ≥ 6 from 2 15 
independent preparations). Open, closed, and shaded columns represent EHFSs, HSs, and 16 
co-suspension of hepatocytes and fibroblasts, respectively. Mean ± SD, **P < 0.01 and *P < 17 
0.05 (two-way or one-way ANOVA). N.S., not significant; N.D., not detected. 18 
19 
Fig. 7. Model of VSLT construction. 20 
21 
Table 1. Human liver tissue resource for primary hepatocyte isolation. 22 
23 
Supplementary Fig. 1. Rapid construction of EHFSs. (A) One-day construction of EHFSs. 24 
28 
(B) Rapid construction of EHFSs using a high density of fibroblasts. Scale bar, 100 μm. 1 
2 
Supplementary Fig. 2. mRNA expression levels of growth factors involved in angiogenesis 3 
of VSLTs at 7 and 14 days after EHFS transplantation. (A) Human VEGF, (B) TGF-β1, (C) 4 
HGF (n = 3 from one cell preparation). Mean ± SD. The expression levels of EHFS were set 5 
as 1.0. N.D., not detected. 6 
7 
Supplementary Fig. 3. HE stained images of hepatocyte tissues under mouse skin. (A) 8 
Hepatocyte tissues from EHFS and (B) from HS at 4 weeks after transplantation. (C) 9 
Hepatocyte tissue from co-suspension of hepatocytes and fibroblasts at 1 week after 10 
transplantation. Scale bar, 100 μm. 11 
12 
Supplementary Fig. 4. In vitro synthesis rates of growth factors involved in angiogenesis 13 
using HepaRG cells. (A) Human PDGF-BB, (B) VEGF, (C) TGF-β1, (D) bFGF, (E) HGF, and 14 
(F) EGF (n = 12 from 2 independent cell preparations). Open, closed, and shaded columns 15 
represent EHFSs, HSs, and FSs, respectively. Mean ± SD, **P < 0.01 and *P < 0.05 (one-way 16 
ANOVA). 17 
18 
Supplementary Fig. 5. In vitro liver-specific functions using HepaRG cells. (A) hALB and 19 
(B) hA1AT (n ≥ 5 from one cell preparation). Open and closed columns represent EHFSs and 20 
HSs, respectively. Mean ± SD, **P < 0.01 and *P < 0.05 (two-way ANOVA). 21 
22 
Supplementary Table 1. TaqMan gene expression assay numbers and GenBank accession 23 








Table 1. Human liver tissue resource for primary hepatocyte isolation. 
Age Sex Disease Viability [%] 
1 70's M Hepatocellular carcinoma 93.1 
2 70's M Intrahepatic cholangiocarcinoma 95.1 
3 70's M Hepatocellular carcinoma 93.2 
4 60's M Hepatocellular carcinoma 91.8 
5 60's F Hepatocellular carcinoma 83.3 
6 80's M Intrahepatic cholangiocarcinoma 89.7 
7 70's M Intrahepatic cholangiocarcinoma 93.1 
8 60's F Cholangiocarcinoma 85.8 
9 70's M Hepatocellular carcinoma 92.4 
10 60's M Metastatic liver tumor 95.4 
11 70's F Intrahepatic cholangiocarcinoma 85.1 
12 70's F Intrahepatic bile duct cystadenocarcinoma 93.1 






Supplementary Table 1. TaqMan gene expression assay numbers and GenBank accession 
numbers for real-time PCR analysis. 
Gene symbol Gene name TaqMan Assay no. GenBank no. 
VEGF Vascular endothelial growth factor A Hs00900055_m1 NM_003376.5 
TGF-β1 Transforming growth factor, beta 1 Hs00998133_m1 NM_000660.4 
HGF Hepatocyte growth factor Hs00300159_m1 NM_000601.4 
ACTB Actin, beta Hs99999903_m1 NM_001101.3 
Supporting Information for 
Vascularized subcutaneous human liver tissue from engineered 
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Supporting Information 
S1. Evaluation of mRNA expression 
S1.1. Total RNA extraction 
   Vascularized subcutaneous human liver tissues (VSLTs) in NOG mice at 7 and 14 days after EHFS 
transplantation, human liver tissues, and engineered hepatocyte/fibroblast sheets at 4 days after hepatocyte 
culture (EHFSs) were used for mRNA extraction using a spin column (NucleoSpin RNA II; Nippon 
Genetics Co. Ltd., Tokyo) according to the manufacturer’s instructions. 
S1.2. cDNA synthesis 
   cDNA was synthesized from 0.2 μg total RNA using a high-capacity cDNA reverse transcription kit 
(Applied Biosystems, Tokyo). The samples were then stored at −20 °C until they were processed for 
polymerase chain reaction (PCR) analysis. 
S1.3. Real-time PCR 
   PCR was performed on an Applied Biosystems StepOnePlus Real-time PCR system using the TaqMan 
Gene Expression Assay Kit (Applied Biosystems; Supplementary Table 1). In brief, PCR amplification was 
performed using a reaction mixture containing 1 μL cDNA sample, 0.5 μL TaqMan Gene Expression Assay 
probe, 5 μL TaqMan Fast Universal PCR Master Mix solution (Applied Biosystems), and 13.5 μL 
nuclease-free water. Each amplification cycle consisted of 1 s at 95 °C and 20 s at 60 °C. The number of 
amplification cycles was 40 cycles. 
S1.4. Data analysis of PCR 
   The comparative cycle time (ΔΔCT) method was used to quantify the gene expression levels according 
to the manufacturer’s protocol. The expression levels of human VEGF, TGF-β1, and HGF were normalized 
to that of ACTB (EHFSs was set as 1.0) to establish the expression of angiogenic growth factors in vivo. 
Data are presented as mean ± standard deviation and corresponded to 3 time points from one cell 
preparation. 
